These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11803608)

  • 1. Abnormal lipid metabolism after renal transplantation.
    Wanner C; Quaschning T
    Ann Transplant; 2001; 6(1):5-8. PubMed ID: 11803608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of dyslipidaemia in renal transplant recipients.
    Wanner C; Quaschning T; Weingärnter K
    Curr Opin Urol; 2000 Mar; 10(2):77-80. PubMed ID: 10785846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical correlation between renal allograft failure and hyperlipidemia.
    Guijarro C; Massy ZA; Kasiske BL
    Kidney Int Suppl; 1995 Dec; 52():S56-9. PubMed ID: 8587285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of antilipidemic therapies in chronic renal allograft failure.
    Wanner C; Bartens W; Galle J
    Kidney Int Suppl; 1995 Dec; 52():S60-2. PubMed ID: 8587286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Derangement of lipid metabolism and its management in renal transplant patients.
    Keane WF
    Miner Electrolyte Metab; 1997; 23(3-6):166-9. PubMed ID: 9387109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular disease after renal transplantation].
    Montanaro D; Gropuzzo M; Tulissi P; Boscutti G; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
    G Ital Nefrol; 2004; 21 Suppl 26():S53-66. PubMed ID: 15732047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic factors and outcome of organ transplantation.
    Dimény E
    Scand J Urol Nephrol Suppl; 1994; 159():1-74. PubMed ID: 7817159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peritubular capillary C4d staining in late acute renal allograft rejection--is it relevant?
    Satoskar AA; Lehman AM; Nadasdy GM; Sedmak DD; Pesavento TE; Henry ML; Pelletier RP; Ferguson RM; Nadasdy T
    Clin Transplant; 2008; 22(1):61-7. PubMed ID: 18217907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of circulating lipid abnormalities in chronic renal allograft rejection.
    Kasiske BL
    Kidney Int Suppl; 1999 Jul; 71():S28-30. PubMed ID: 10412732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence evolution and impact of cardiovascular risk factors on allograft and renal transplant patient survival.
    Díaz JM; Gich I; Bonfill X; Solà R; Guirado L; Facundo C; Sainz Z; Puig T; Silva I; Ballarín J
    Transplant Proc; 2009; 41(6):2151-5. PubMed ID: 19715859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic abnormalities in renal transplant recipients. Risk factors and predictors of chronic graft dysfunction?
    Dimény E; Fellström B
    Nephrol Dial Transplant; 1997 Jan; 12(1):21-4. PubMed ID: 9027767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular disease after renal transplantation.
    Kasiske BL
    Semin Nephrol; 2000 Mar; 20(2):176-87. PubMed ID: 10746859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ
    Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of hyperlipidaemia on graft and patient outcome in renal transplantation.
    Del Castillo D; Cruzado JM; Manel Díaz J; Beneyto Castelló I; Lauzurica Valdemoros R; Gómez Huertas E; Checa Andrés MD
    Nephrol Dial Transplant; 2004 Jun; 19 Suppl 3():iii67-71. PubMed ID: 15192140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidemia and its management after renal transplantation.
    Andany MA; Kasiske BL
    J Nephrol; 2001; 14 Suppl 4():S81-8. PubMed ID: 11798152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.
    Khalkhali HR; Ghafari A; Hajizadeh E; Kazemnejad A
    Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E gene polymorphism in renal transplant recipients: effects on lipid metabolism, atherosclerosis and allograft function.
    Kahraman S; Kiykim AA; Altun B; Gençtoy G; Arici M; Gulsun M; Erdem Y; Yasavul U; Turgan C; Cağlar S
    Clin Transplant; 2004 Jun; 18(3):288-94. PubMed ID: 15142050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant hyperlipidemia: mechanisms and management.
    Massy ZA; Kasiske BL
    J Am Soc Nephrol; 1996 Jul; 7(7):971-7. PubMed ID: 8829110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
    Valantine H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S187-93. PubMed ID: 15093804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.